Genovis to launch FabULOUS™ for analysis and characterization of antibody molecules

        Print
| Source: Genovis AB
Genovis is launching FabULOUS at the Well Characterized Biologicals conference
in Washington DC on October 21. The product, which complements FabRICATOR, has
already been tested by key customers in Europe and the US with positive results
and is now being launched in a first phase through in-house sales and later
through the company's global distributor network.
“This new product is a completely new enzyme that offers our customers several
alternative strategies for characterization of antibody molecules. Fabulous is a
great addition to FabRICATOR and by using the two products together, the
customer gets a fast method to characterize the hinge region of an antibody in
detail, which is important in many antibody drug conjugate (ADC) drug
candidates. Our R & D activities focus on products that can save time, simplify
work and improve the quality of analyses for our customers and FabULOUS is a
great example of it,” says Sarah Fredriksson, CEO of Genovis.

Genovis has developed the product FabULOUS, which can quickly generate fragments
from IgG molecules. FabULOUS is a recombinant enzyme that cleaves IgG
specifically, thereby generating three intact fragments of an antibody. The
yield is high, the reaction rate is fast and the enzyme does not generate any
further fragmentation. Customers will primarily use the product for screening of
new drug substances and quality control of new antibody-based drugs.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00